<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3073">
  <stage>Registered</stage>
  <submitdate>26/01/2011</submitdate>
  <approvaldate>26/01/2011</approvaldate>
  <nctid>NCT01292655</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors</studytitle>
    <scientifictitle>Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CA216-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-906024

Experimental: Arm A1 (Escalation): BMS-906024 - BMS-906024 solution intravenously as specified

Experimental: Arm A2 (Expansion): BMS-906024 - BMS-906024 solution intravenously as specified

Experimental: Arm B1 (Escalation): BMS-906024 - BMS-906024 solution intravenously as specified

Experimental: Arm B2 (Expansion): BMS-906024 - BMS-906024 solution intravenously as specified


Treatment: drugs: BMS-906024


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of subjects with adverse events as a measure of safety and tolerability</outcome>
      <timepoint>Weekly assessments until study discontinuation due to disease progression or unacceptable adverse event as well as an assessment 30 day after treatment discontinuation with an average time on study expected to be &lt;1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor assessments using response evaluation criteria in solid tumors (RECIST) v1.1</outcome>
      <timepoint>Tumor assessments at least every 8 weeks during treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PD changes from baseline in the expression of Notch pathway-related genes in surrogate tissues (peripheral blood cells) and tumor biopsies</outcome>
      <timepoint>PD changes from baseline during the first 4-5 weeks of dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters for BMS-906024 and its metabolite BMS-911557, maximum observed concentration (Cmax)</outcome>
      <timepoint>PK at multiple time points during the first 8 weeks of dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters for BMS-906024 and its metabolite BMS-911557, minimum observed concentration (Cmin)</outcome>
      <timepoint>PK at multiple time points during the first 8 weeks of dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters for BMS-906024 and its metabolite BMS-911557, time to reach maximum observed concentration (Tmax)</outcome>
      <timepoint>PK at multiple time points during the first 8 weeks of dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters for BMS-906024 and its metabolite BMS-911557, terminal phase elimination half-life (T-Half)</outcome>
      <timepoint>PK at multiple time points during the first 8 weeks of dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters for BMS-906024 and its metabolite BMS-911557, accumulation index (AI)</outcome>
      <timepoint>PK at multiple time points during the first 8 weeks of dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters for BMS-906024 and its metabolite BMS-911557, area under the concentration-time curve (AUC)</outcome>
      <timepoint>PK at multiple time points during the first 8 weeks of dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        

          -  Subjects with advanced or metastatic solid tumors (non-hematologic refractory to or
             relapsed from standard therapies or for which there is no known effective treatment
             during dose escalation

          -  Subjects with squamous non-small cell lung cancer and triple-negative breast cancer or
             other solid tumor types for which Notch activation has been demonstrated (such as
             pancreatic, ovarian and melanoma) during dose expansion

          -  Biopsy accessible tumor (may be waived under certain circumstances)

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Adequate organ and bone marrow function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Infection

          -  Elevated triglycerides

          -  Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel
             disease (IBD)]

          -  Taking medications known to increase risk of Torsades De Pointes</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>3/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>94</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>22/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Local Institution - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects
      with advanced or metastatic solid tumors who no longer respond to or have relapsed from
      standard therapies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01292655</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>